Last reviewed · How we verify
Intravenous methylene blue administration
Methylene blue acts as a redox agent and monoamine oxidase inhibitor that reduces oxidative stress and modulates mitochondrial function.
Methylene blue acts as a redox agent and monoamine oxidase inhibitor that reduces oxidative stress and modulates mitochondrial function. Used for Vasoplegic syndrome (phase 3), Septic shock with vasodilation.
At a glance
| Generic name | Intravenous methylene blue administration |
|---|---|
| Also known as | methylene blue administration, MB administration |
| Sponsor | Seoul National University Hospital |
| Drug class | Redox agent / Monoamine oxidase inhibitor |
| Target | Mitochondrial electron transport chain; Monoamine oxidase |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry / Critical Care |
| Phase | Phase 3 |
Mechanism of action
Methylene blue functions as an electron carrier in mitochondrial respiration, enhancing ATP production and reducing reactive oxygen species. It also inhibits monoamine oxidase and has anti-inflammatory properties, making it potentially useful in conditions involving mitochondrial dysfunction and oxidative stress-related pathology.
Approved indications
- Vasoplegic syndrome (phase 3)
- Septic shock with vasodilation
Common side effects
- Blue discoloration of urine and skin
- Nausea
- Headache
- Serotonin syndrome (rare, with serotonergic agents)
Key clinical trials
- Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses (PHASE2)
- A Multidisciplinary Perioperative Pain Management (NA)
- A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses (PHASE2)
- Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study (PHASE1)
- Methylene Blue and Postoperative Neurocognitive Disorders (NA)
- Outcomes for Anesthesiologist-Led Care of Analgesic Protocol in Anorectal Surgery (NA)
- Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients (PHASE4)
- Thoracic Paravertebral Block With Methylene Blue Visual Confirmation for Postoperative Pain After VATS Lobectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: